1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)" is currently closed and not accepting applications.
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), National Institute on Aging (NIA). This R01 funding opportunity supports research into novel mechanisms underlying neuropsychiatric symptoms (NPS) in Alzheimer's Dementia. Projects may or may not include a clinical trial component.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) (PAR-23-207) | UC Irvine School of Medicine Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) (PAR-23-207) The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD).
The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R01 mechanism, while the companion announcement PAR-23-208 uses the R21 mechanism.
High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. 2025 Deadline 1 : Jun 05, 2025 - 5:00:PM 2025 Deadline 2 : Oct 05, 2025 - 5:00:PM 2026 Deadline 1 : Feb 05, 2026 - 5:00:PM 2026 Deadline 2 : Jun 05, 2026 - 5:00:PM National Institutes of Health (NIH) Neurology/Neurodegenerative
According to the current listing, eligibility includes: Nonprofits, universities, state/local governments, for-profit organizations. Applicants should confirm final requirements in the official notice before submission. Confirm the full requirements in the official notice before applying.
The published deadline was September 8, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) is funded by National Institutes of Health (NIH), National Institute on Aging (NIA). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article